Stock 600196 SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Equities

600196

CNE000000X38

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
23.19 CNY +1.35% Intraday chart for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. +3.02% -7.35%
Apr. 24 Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator MT
Apr. 18 China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Tranche Update on Shanghai Fosun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.
CI
Fosun Pharma's 2023 Attributable Profit Declines, Misses Estimates
MT
Shanghai Fosun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.
CI
Shanghai Fosun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023
CI
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Shanghai Fosun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
CI
Fosun Pharma Unit Gets China OK for Phase I Trial for Solid Tumor Drug
MT
Fosun Pharma Chairman Proposes Buyback of Up to 200 Million Yuan
MT
Fosun Pharma Subsidiaries Get Nod to Trial Leukemia Drugs
MT
Shanghai Fosun Unit Gets Clearance For China Phase II Trial of Amyloidosis Drug
MT
Shanghai Fosun Pharmaceutical Co., Ltd. Enter into Mutual Supply Framework Agreement with Fosun International Limited
CI
Chinese Drug Regulator Accepts Fosun Pharma Subsidiary's Application for Diet Supplement
MT
Fosun Pharmaceutical's Unit Gets Greenlight to Test Cancer Drug in US, China
MT
Fosun Pharma Unit Obtains Marketing Rights to Desmopressin in China
MT
India's Gland Pharma misses Q2 profit view on higher expenses
RE
Fosun Pharmaceutical Posts 44% Drop in Q3 Profit
MT
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Shanghai Fosun Pharmaceutical Co., Ltd. acquired additional 40% stake in Shanghai Fujian Equity Investment Fund Management Co., Ltd. from Shanghai Fosun Health Industry Holding Company Limited for CNY 22.2 million.
CI
Jiangsu Xingsheng Xinhui Pharmaceutical Co., Ltd. Receives Approval from the National Medical Products Administration of China for the Clinical Trial of XS-03 Tablets
CI
Fosun Pharma's Unit Gets Nod to Test Drug Licensed by Switzerland's Neovii Pharmaceuticals
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600196 Stock
  4. News Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  5. Highlights